CB-03-01 Clascoterone CAS: 19608-29-8

CAS NO: 19608-29-8
CB-03-01 Clascoterone
Chemical Name: Clascoterone
Molecular Formula: C24H34O5
Formula Weight: 402.52
CAS No.: 19608-29-8
Description Review
Description

CB-03-01, also known as Clascoterone or Breezula, is a topical drug that was originally developed as a treatment for acne. However, it has gained attention as a potential treatment for hair loss due to its ability to block androgen receptors in the scalp.

Chemical Name:

The chemical name for CB-03-01 (Clascoterone) is (1R,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl 2,2,2-trifluoroethanolate.

Molecular Formula:

The molecular formula of CB-03-01 (Clascoterone) is C27H34F3O3.

Formula Weight:

The formula weight of CB-03-01 (Clascoterone) is 466.56 g/mol.

CAS No:

The CAS number of CB-03-01 (Clascoterone) is 19608-29-8.

Top Ten Keywords from Google and Synonyms:

  1. Hair Loss Treatment
  2. Androgen Receptor Antagonist
  3. Topical Solution
  4. Acne Medication
  5. Alopecia Treatment
  6. Testosterone Blocker
  7. Dihydrotestosterone Inhibitor
  8. Anti-Androgen Agent
  9. Seborrheic Dermatitis Treatment
  10. Breezula

Health Benefits of CB-03-01 (Clascoterone):

CB-03-01 (Clascoterone) is believed to provide various health benefits due to its ability to block androgen receptors in the scalp. Some of the potential benefits of CB-03-01 (Clascoterone) include:

  1. Hair Regrowth: CB-03-01 (Clascoterone) may promote hair regrowth and prevent further hair loss in individuals with androgenetic alopecia.

  2. Reduced Sebum Production: CB-03-01 (Clascoterone) may reduce sebum production in the scalp and improve symptoms of seborrheic dermatitis.

Potential Effects:

CB-03-01 (Clascoterone) can produce a range of effects depending on the dosage and individual response. Some of the potential effects of CB-03-01 (Clascoterone) include:

  1. Improved Hair Growth: CB-03-01 (Clascoterone) may improve hair growth by blocking androgen receptors in the scalp.

  2. Reduced Sebum Production: CB-03-01 (Clascoterone) may reduce sebum production in the scalp and improve symptoms of seborrheic dermatitis.

Product Mechanism:

CB-03-01 (Clascoterone) works by blocking androgen receptors in the scalp, which reduces the action of dihydrotestosterone (DHT). DHT is known to contribute to hair loss in individuals with androgenetic alopecia. By blocking androgen receptors, CB-03-01 (Clascoterone) may promote hair growth and prevent further hair loss.

Safety:

CB-03-01 (Clascoterone) can be safe when used appropriately and under medical supervision. However, it can cause adverse effects if misused or abused. Some of the potential side effects of CB-03-01 (Clascoterone) include:

  1. Skin Irritation: CB-03-01 (Clascoterone) may cause skin irritation or allergic reactions in some individuals.

  2. Gastrointestinal Disturbances: CB-03-01 (Clascoterone) may cause gastrointestinal disturbances, such as nausea or diarrhea, in some individuals.

Dosing Information:

The appropriate dose of CB-03-01 (Clascoterone) depends on several factors such as age, weight, and health status. It is essential to follow dosing instructions carefully and not exceed the recommended dose.

Conclusion:

CB-03-01 (Clascoterone) is a topical drug that was originally developed as a treatment for acne but has gained attention as a potential treatment for hair loss. While CB-03-01 (Clascoterone) may provide some health benefits, it should only be used under medical supervision and with caution due to its potential side effects. Additionally, more research is needed to fully understand its safety and efficacy in humans.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us